The landscape of diabetes care is evolving with the emergence of transdermal GLP-1 delivery . These novel patches offer a potentially less invasive alternative to shots for individuals managing diabetes mellitus type 2 . Such a system deliver glucagon-like peptide-1 directly through the epidermis, bypassing the need for frequent semaglutide cost in